Last reviewed · How we verify
Zemuron®
At a glance
| Generic name | Zemuron® |
|---|---|
| Also known as | Rocuronium bromide |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy (NA)
- Two Video Laryngoscopes (Laringocel® and C-MAC®) for First-Attempt Intubation in Adults Undergoing Elective Surgery (NA)
- Low Pressure Pneumoperitoneum and Postoperative Ileus (NA)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
- Impact of Interscalene Block Combined With General Anesthesia on Burst Suppression in Shoulder Surgery Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zemuron® CI brief — competitive landscape report
- Zemuron® updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI